Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 55Ovarian Neoplasms 39Carcinoma, Hepatocellular 39Neoplasms 25Fallopian Tube Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Endometrial Neoplasms 14Glioblastoma 11Breast Neoplasms 11Brain Neoplasms 11Colonic Neoplasms 10Neoplasm Metastasis 9Lung Neoplasms 8Liver Neoplasms 8Uterine Cervical Neoplasms 7Stomach Neoplasms 6Rectal Neoplasms 6Glioma 6Biliary Tract Neoplasms 6Carcinoma, Ovarian Epithelial 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Neoplasms, Nerve Tissue 3Gastrointestinal Neoplasms 3

Interventions

durvalumab 1Immunotherapy 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Bevacizumab × 90 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡